Chronická myeloidní leukemie - od poznání patogeneze k cílené léčbě onemocnění
| Title in English | Chronic myeloid leukemia - from understanding pathogenesis to targeted therapy |
|---|---|
| Authors | |
| Year of publication | 2022 |
| Type | Article in Periodical |
| Magazine / Source | Acta medicinae |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.actamedicinae.cz/ocasopise.htm |
| Keywords | chronic myeloid leukemia; tyrosine kinase inhibitors; remission without the need for therapy |
| Description | Chronic myeloid leukaemia has an exclusive position among other cancers. It was the first malignancy that was linked to a genetic abnormality in the form of a truncated chromosome 22 carrying a pathological fusion gene Imatinib, an inhibitor of the pathological BCR-ABL1 tyrosine kinase responsible for the pathogenesis of the disease, was the first representative of this class of small targeted molecules introduced into the field and the fastest ever approved anti-cancer drug. With imatinib, followed by higher generation tyrosine kinase inhibitors, a fatal disease became a manageable disease with a survival expectancy comparable to the general population. The burden of initially lifelong therapies is succeeding in some patients by controlled withdrawal of therapy in an attempt to achieve remission without the need for treatment or to mitigate it by optimising dosing and the development of new effective and non-toxic drugs, procedures that are relevant not only in the context of difficult treatment but also in the hope of improving the outcome of the treatment process itself. |
| Related projects: |